Eli Lilly banks on tirzepatide’s clinical edge as GLP-1 generics loom (Soban News)

Lilly positions tirzepatide as a clinically superior option as semaglutide patent expiry triggers a wave of generics, intensifying competition in India’s diabetes and obesity market​Lilly positions tirzepatide as a clinically superior option as semaglutide patent expiry triggers a wave of generics, intensifying competition in India’s diabetes and obesity market ​Latest News [ SOBAN NEWS: International and National ]